Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Eubanks, Terri
NCT05574478: Metastatic Breast Cancer-Specific Prognostic Tool	Active, not recruiting	N/A	19	US	Patients and Caregivers Qualitative Interview	UNC Lineberger Comprehensive Cancer Center, Conquer Cancer Foundation, Doris Duke Charitable Foundation	Metastatic Breast Cancer	02/25	02/26
HARMONY, NCT03769415: Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA	Recruiting	N/A	500	US	Intrinsic Subtyping of Primary Breast Cancer	UNC Lineberger Comprehensive Cancer Center, Veracyte, Inc., Breast Cancer Research Foundation	Breast Cancer	12/30	12/30
Ray, Emily
Saci-IO TNBC, NCT04468061: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Jan 2022 - Jun 2022 : Initiation of P3 trial in combination with keytruda for 1L mTNBC	Recruiting	2	110	US	Sacituzumab Govitecan, IMMU-132, Trodelvy, Pembrolizumab, Keytruda	Dana-Farber Cancer Institute, Gilead Sciences, Merck Sharp & Dohme LLC	Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative	04/26	04/29
NCT05722847: Risk Stratification for Patients With Hospital-diagnosed Advanced Lung Cancer	Active, not recruiting	N/A	18	US		UNC Lineberger Comprehensive Cancer Center	Lung Cancer	01/25	05/25
NCT05574478: Metastatic Breast Cancer-Specific Prognostic Tool	Active, not recruiting	N/A	19	US	Patients and Caregivers Qualitative Interview	UNC Lineberger Comprehensive Cancer Center, Conquer Cancer Foundation, Doris Duke Charitable Foundation	Metastatic Breast Cancer	02/25	02/26
NCT05440929: Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians	Recruiting	N/A	15	US	Clinician Qualitative Interview	UNC Lineberger Comprehensive Cancer Center, Conquer Cancer Foundation	Metastatic Breast Cancer, End of Life	06/25	07/25